enGene Inc (ENGNW)
FDA Grants RMAT Designation for enGenes Detalimogene, Enabling Potential for Expedited Review in High-Risk, Non-Muscle Invasive Bladder Cancer
SenesTech Inc (SNES)
Amneal Pharmaceuticals Inc. (AMRX)
Amneal Highlights Positive Topline Results from Confirmatory Clinical Study of Biosimilar Candidate to XOLAIR(R) (omalizumab), Developed by Kashiv BioSciences
OPKO Health Inc. (OPK)
OPKO Health and Entera Bio Abstract for First-in-Class Dual GLP-1/Glucagon Tablet Candidate for Patients with Obesity and Metabolic Disorders Selected for Presentation at the ENDO 2025 Annual Meeting
Corvus Pharmaceuticals Inc (CRVS)
Corvus Pharmaceuticals Announces Partner Angel Pharmaceuticals Received IND Approval for a Phase 1b/2 Clinical Trial of Soquelitinib in China for the Treatment of Atopic Dermatitis
Soleno Therapeutics Inc. (SLNO)
Soleno Therapeutics Highlights New Data on VYKAT(TM) XR at the 2025 United in Hope: International Prader-Willi Syndrome Conference
Ovid Therapeutics Inc (OVID)
Ovid Therapeutics Enters Agreement with Immedica Pharma AB for Sale of Future Ganaxolone Royalties
Evaxion Biotech A/S (EVAX)
Evaxion expands R&D pipeline with new vaccine program targeting Group A Streptococcus
Zyversa Therapeutics Inc (ZVSA)
ZyVersa Therapeutics Announces Share Purchase Agreement for up to $10 Million in Partnership with Williamsburg Venture Holdings to Fund Clinical Development of Cholesterol Efflux Mediator™ VAR 200
Clearmind Medicine Inc (CMND)
Clearmind Medicine Enrolls First Patient in its Clinical Trial for Alcoholism Treatment
Phio Pharmaceuticals Corp. (PHIO)
Phio Pharmaceuticals Announces Positive Safety Monitoring Committee Recommendation to Advance INTASYL PH-762 Skin Cancer Clinical Trial to Fifth Dose Escalation Cohort
Roivant Sciences Ltd (ROIV)
Arbutus Biopharma Corporation (ABUS)
Takeda Pharmaceutical Co., Ltd. (TKPHF)
Biogen Inc (BIIB)
Biogen to Advance Investigational Spinal Muscular Atrophy Asset to Registrational Studies Based on Positive Interim Phase 1 Results